Inclusion Criteria:

          -  Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) histology (confirmed
             by either histology or cytology) with documented activating Epidermal Growth Factor
             Receptor (EGFR) mutation

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a minimum
             life expectancy of 12 weeks

          -  Acquired resistance on previous first-line osimertinib. Participants must meet both of
             the following 2 criteria:

          -  Radiological documentation of disease progression on first-line osimertinib

          -  Objective clinical benefit documented during previous osimertinib therapy, defined by
             either partial or complete radiological response, or durable stable disease (SD) (SD
             should last greater than (>) 6 months after initiation of osimertinib

          -  Have received only first-line osimertinib as a prior line of therapy in the non
             curative advanced or metastatic NSCLC setting

          -  MET amplification as determined by either FISH testing (central or local) on tumor
             tissue (TBx) or central blood-based next generation sequencing (LBx). Tumor and blood
             samples must be collected following progression on prior first-line osimertinib at
             Prescreening

          -  Submission of tumor tissue and blood sample obtained after progression on first-line
             osimertinib, is mandatory for all patients for MET amplification testing

          -  Submission of tumor tissue during Prescreening or Screening is mandatory for patients
             with tumor tissue tested by local FISH, to confirm MET amplification status. Central
             confirmation is not mandated prior to the start of study treatment

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Spinal cord compression or brain metastasis unless asymptomatic, stable or not
             requiring steroids for at least 2 weeks prior to start of study intervention

          -  Any unresolved toxicity Grade 2 or more according to National cancer institute common
             terminology criteria for adverse events( NCI-CTCAE) version 5, from previous
             anticancer therapy with the exception of alopecia

          -  Inadequate hematological, liver and renal function

          -  Impaired cardiac function

          -  History of interstitial lung disease(ILD) or interstitial pneumonitis including
             radiation pneumonitis that required steroid treatment

          -  Hypertension uncontrolled by standard therapies (not stabilized to < 150/90 millimeter
             of mercury (mmHg)

          -  Contraindication to the administration of osimertinib

          -  Other protocol defined exclusion criteria could apply.